GAMMA Investing LLC Buys 1,346 Shares of Moderna, Inc. (NASDAQ:MRNA)

GAMMA Investing LLC raised its holdings in Moderna, Inc. (NASDAQ:MRNA) by 45.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,340 shares of the company’s stock after buying an additional 1,346 shares during the period. GAMMA Investing LLC’s holdings in Moderna were worth $515,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Ogorek Anthony Joseph NY ADV purchased a new position in Moderna in the 4th quarter worth approximately $27,000. Cedar Wealth Management LLC grew its stake in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the last quarter. Arlington Trust Co LLC increased its position in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares in the last quarter. Westside Investment Management Inc. bought a new stake in Moderna in the 1st quarter worth about $32,000. Finally, Rise Advisors LLC grew its holdings in shares of Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after acquiring an additional 286 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on MRNA. William Blair restated a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. UBS Group upped their target price on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price target on shares of Moderna in a research note on Thursday, June 27th. The Goldman Sachs Group reduced their price target on Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a research report on Friday. Finally, Royal Bank of Canada decreased their price target on Moderna from $160.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $126.59.

Insider Activity

In other news, President Stephen Hoge sold 255 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $120.96, for a total transaction of $30,844.80. Following the transaction, the president now directly owns 1,486,508 shares of the company’s stock, valued at $179,808,007.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Moderna news, CFO James M. Mock sold 648 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total value of $105,280.56. Following the transaction, the chief financial officer now directly owns 5,726 shares of the company’s stock, valued at $930,303.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Stephen Hoge sold 255 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the transaction, the president now directly owns 1,486,508 shares in the company, valued at approximately $179,808,007.68. The disclosure for this sale can be found here. Insiders have sold a total of 396,239 shares of company stock valued at $55,563,937 over the last quarter. Company insiders own 15.70% of the company’s stock.

Moderna Trading Down 8.1 %

NASDAQ MRNA traded down $7.59 during trading hours on Friday, reaching $86.58. The company’s stock had a trading volume of 10,332,912 shares, compared to its average volume of 3,496,157. The firm has a fifty day simple moving average of $129.81 and a 200-day simple moving average of $115.22. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47. The stock has a market cap of $33.18 billion, a P/E ratio of -5.53 and a beta of 1.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($3.62) earnings per share. Equities analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.